← Back to Search

PCplanner for Idiopathic Pulmonary Fibrosis

N/A

Waitlist Available

Led By Christopher Cox, MD

Research Sponsored by Duke University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 16 weeks

Awards & highlights

Study Summary

This trial will test whether the PCplanner mobile app can help patients with idiopathic pulmonary fibrosis (a lung disease) and their clinicians to address needs and have advance care planning discussions.

Eligible Conditions

Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 16 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 16 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acceptability of intervention

Completion of intervention

Documentation of advance care planning in electronic health record

+1 more

Secondary outcome measures

Change in EuroQol - 5 Dimension (EQ-5D) score

Change in General Anxiety Disorder-7 (GAD-7) score

Change in Needs; Existential concerns; Symptoms; and Therapeutic interaction (NEST) scale

+4 more

Other outcome measures

Number of hospitalizations during study

Referral to hospice during study

Referral to palliative care specialist during study

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: PCplanner mobile app platformExperimental Treatment1 Intervention

Participants who are randomized to the intervention arm will complete surveys at 3 timepoints and will be given resources on advance care planning via PCplanner, the mobile app platform. They will receive a telephone call by the study team about a week after enrollment to answer any questions about the resources provided. If needs and questions are not resolved quickly after the clinic visit, then another layer of patient support with a telephone call by a palliative care specialist will be provided to the participant to help develop potential management plans.

Group II: Usual CareActive Control1 Intervention

Participants who are randomized to the usual care arm will complete surveys at 3 timepoints and receive usual care by pulmonary clinician.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PCplanner

2021

N/A

~200

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor

2,358 Previous Clinical Trials

3,420,026 Total Patients Enrolled

6 Trials studying Idiopathic Pulmonary Fibrosis

2,420 Patients Enrolled for Idiopathic Pulmonary Fibrosis

Christopher Cox, MDPrincipal InvestigatorDuke Health

2 Previous Clinical Trials

254 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the ambitions of this experiment?

"This medical study seeks to measure the completion of intervention over a period of up to 16 weeks. Secondary objectives focus on changes in Patient Health Questionnaire-9 (PHQ-9), EuroQol - 5 Dimension (EQ-5D) and Patient Health Questionnaire 10(PHQ-10). A diminished PHQ-9 score suggests no or mild depression, whereas an increased reading implies more severe distress; EQ 5D results generally range from 0 (poor quality of life) to 1 (exemplary wellbeing); lastly, higher PHQ–10 scores indicate symptoms are becoming increasingly bothersome."

Answered by AI

Are there still opportunities to take part in this research endeavor?

"Information from clinicaltrials.gov reveals that this trial is actively enrolling candidates; it was first posted on March 16th 2022 and has been recently updated with the same date."

Answered by AI

How many participants are being enrolled in this research investigation?

"Affirmative. Clinicaltrials.gov has the records of this medical research project, which was initially made public on March 16th 2022 and recently revised on the same date. 30 participants must be sourced from one single location for the trial to continue as planned."

Answered by AI

Recent research and studies

Archives of Internal MedicineJournal

Differences in Health Care Utilization at the End of Life Among Patients with Chronic Obstructive Pulmonary Disease and Patients with Lung Cancer

Au, David H., Edmunds M. Udris, Stephan D. Fihn, Mary B. McDonell, and J. Randall Curtis. 2006. “Differences in Health Care Utilization at the End of Life Among Patients with Chronic Obstructive Pulmonary Disease and Patients with Lung Cancer”. Archives of Internal Medicine. American Medical Association (AMA). doi:10.1001/archinte.166.3.326.

Advances in TherapyJournal

Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey

Olson, Amy, Nadine Hartmann, Padmaja Patnaik, Laura Wallace, Rozsa Schlenker-Herceg, Mouhamad Nasser, Luca Richeldi, Anna-Maria Hoffmann-Vold, and Vincent Cottin. 2020. “Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey”. Advances in Therapy. Springer Science and Business Media LLC. doi:10.1007/s12325-020-01578-6.

ChestJournal

Predicting Survival Across Chronic Interstitial Lung Disease

Ryerson, Christopher J., Eric Vittinghoff, Brett Ley, Joyce S. Lee, Joshua J. Mooney, Kirk D. Jones, Brett M. Elicker, et al.. 2014. “Predicting Survival Across Chronic Interstitial Lung Disease”. Chest. Elsevier BV. doi:10.1378/chest.13-1474.

Journal of Pain and Symptom ManagementJournal